## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tesamorelin-chemo-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tesamorelin-chemo-neuropathy` v2 · content_hash `cd83255ff7873db6…` · thread_head genesis · 25 DIVs
- **thesis (c1):** No published human trials test Tesamorelin for CIPN.
  - c2 [human/active] Ongoing Phase 2 trial (NCT03150511) tests Tesamorelin after peripheral nerve injury repair for motor/sensory recovery.
  - c3 [human/active] Gabapentin/pregabalin show modest pain reduction in CIPN human trials.
  - c4 [mechanistic/active] Tesamorelin raises GH and IGF-1, which support axon regeneration in preclinical nerve injury models.
  - c5 [anecdotal/active] FAERS data associate Tesamorelin with increased carpal tunnel reports.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tesamorelin-chemo-neuropathy`
- **title:** Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show
- **url:** https://miscsubjects.com/a/tesamorelin-chemo-neuropathy
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:21.257Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)

Chemotherapy agents damage peripheral nerves. Platinum drugs, taxanes, and vinca alkaloids hit sensory axons first. This leads to axon degeneration, myelin sheath disruption, and slowed nerve conduction. Inflammation and oxidative stress add layers. Symptoms often include numbness, tingling, pain, and balance issues that can persist or worsen after treatment ends (coasting effect). The core issue is repair lagging behind ongoing degeneration. No single drug repairs the nerve; most options address symptoms only.

## Why Tesamorelin might help you

1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.
2. **Therefore for you:** If the GH/IGF-1 axis and tissue repair pathways are part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.

Tesamorelin stimulates growth hormone release. Higher GH can raise IGF-1 levels. IGF-1 supports axon growth and Schwann cell function in lab models. If your neuropathy involves stalled regeneration, this pathway could matter. It does not directly block pain signals.

## Why Gabapentin / pregabalin matters for you

**Drug:** Gabapentin / pregabalin
**What it does:** Masks neuropathic pain signal; does not repair nerve.
**Therefore for you:** This drug suppresses a signal. It can reduce pain intensity so daily function improves, but it does not address axon damage or support regeneration. Symptom relief may let you stay active while repair pathways (if any) work, yet it trades off by not fixing the underlying breakdown.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **Tesamorelin** → GH axis / visceral fat

Tesamorelin aims at a repair layer via GH/IGF-1. Gabapentin/pregabalin handles symptom load. They address different parts: one potential regeneration support, one signal suppression. No overlap in mechanism, so they could run in parallel if both layers matter to you.

## What the evidence actually shows

No published human trials test Tesamorelin specifically for CIPN. One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) examines Tesamorelin after surgical repair of peripheral nerve injuries such as ulnar nerve lacerations. It measures motor and sensory recovery over one year. Results are not yet available (human tier: none for CIPN; preclinical/mechanistic only for nerve regeneration concepts).

Animal data on GH/IGF-1 and nerve repair exist but do not include Tesamorelin or CIPN models directly. FAERS database analysis links Tesamorelin reports to carpal tunnel syndrome (anecdotal tier from pharmacovigilance).

Gabapentin and pregabalin have multiple human trials showing modest pain reduction in CIPN and other neuropathies (human tier).

## What scientists say

Researchers note GH/IGF-1 can promote axonal regeneration and reduce muscle atrophy after nerve injury in preclinical settings. The Johns Hopkins trial tests whether Tesamorelin translates this to humans after traumatic nerve cuts. No statements exist on CIPN specifically. IGF-1 mechanisms remain under study for various neuropathies (mechanistic tier).

## What people say on Reddit

Limited mentions. One post discusses the peripheral nerve injury trial but no personal CIPN experience. Other threads note Tesamorelin side effects like hand numbness or wrist discomfort in non-CIPN users. No consistent reports of CIPN improvement (anecdotal tier, very low volume).

## What people say on X

No identifiable posts linking Tesamorelin use to CIPN outcomes or experiences (anecdotal tier: none found).

## What we do not know

Whether Tesamorelin improves CIPN symptoms, nerve conduction, or quality of life in humans remains unknown. The ongoing trial targets traumatic injuries, not chemo-related damage. Long-term effects on cancer survivors, interactions with chemo history, and optimal timing are unstudied. IGF-1 elevation safety after cancer treatment lacks specific data.

## Safety and limits

Tesamorelin is FDA-approved for HIV-associated lipodystrophy; common effects include injection site reactions, joint pain, and fluid retention. It raises IGF-1, which requires monitoring in some contexts. Gabapentin/pregabalin carry dizziness, sedation, and dependence risks with long-term use. Neither compound repairs nerves. All information here is for evidence review only; consult qualified clinicians for personal health decisions.

## Claims (5)

- **c1** [human w=0.8] No published human trials test Tesamorelin for CIPN.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] Ongoing Phase 2 trial (NCT03150511) tests Tesamorelin after peripheral nerve injury repair for motor/sensory recovery.
  - who_claims: grok/grok-4.3
  - sources: s2, s1
- **c3** [human w=0.8] Gabapentin/pregabalin show modest pain reduction in CIPN human trials.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [mechanistic w=0.3] Tesamorelin raises GH and IGF-1, which support axon regeneration in preclinical nerve injury models.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c5** [anecdotal w=0.3] FAERS data associate Tesamorelin with increased carpal tunnel reports.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 11 edges)
- full graph: https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `b0ef84552c38db7e`

### s1 · clinical_trial · ok
- title: Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
- url: https://clinicaltrials.gov/study/NCT03150511
- summary: Phase 2 trial for peripheral nerve injury recovery; no CIPN arm.
- quote: The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.
- claim_ids: c1, c2
- hash: `ad50d08ba5c80718`

### s2 · clinical_trial · ok
- title: Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
- url: https://clinicaltrials.gov/study/NCT03150511
- summary: Describes mechanism hypothesis via GH axis.
- quote: Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve Injury and Repair
- claim_ids: c2, c4
- hash: `037aef4281f05eea`

### s3 · review · ok
- title: Chemotherapy-Induced Peripheral Neuropathy
- url: https://www.mypcnow.org/fast-fact/chemotherapy-induced-peripheral-nearopathy/
- summary: Notes symptomatic management options including gabapentinoids.
- quote: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity for many anti-cancer agents.
- claim_ids: c3
- hash: `cdb1356edc66d950`

### s4 · pubmed · ok
- title: Carpal Tunnel Syndrome Attributed to Medication Use
- url: https://pubmed.ncbi.nlm.nih.gov/40510111/
- summary: Adverse event reporting association.
- quote: ten drugs were found to have significant overreporting of CTS, including ... tesamorelin (ROR=20.7...
- claim_ids: c5
- hash: `b0ef84552c38db7e`

## Provenance (2 model passes)
- chain valid: yes · head: `2e271f702cacc266`

- write · grok/grok-4.3 · 2026-06-29T23:24 · hash `bbaa61e294fd`
- voxel_divide · owner · 2026-07-17T02:42 · hash `2e271f702cac`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tesamorelin-chemo-neuropathy","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tesamorelin-chemo-neuropathy|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tesamorelin-chemo-neuropathy|tier|assertion`
- **iMessage ask:** `tesamorelin-chemo-neuropathy|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tesamorelin-chemo-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*